Thyroseq V3 molecular testing for fine needle aspiration biopsy samples of thyroid nodules

The contract solicitation 75N98026Q00822, issued by the National Institutes of Health under the Department of Health and Human Services, seeks a firm-fixed-price provider to perform Thyroseq V3 molecular testing on up to 20 fine needle aspiration biopsy samples of indeterminate thyroid nodules annually. The work will be performed at the NIH campus in Bethesda, Maryland, where the NCI cytopathology unit will handle sample collection and shipping, while the contractor is responsible for delivering comprehensive genetic analysis using next-generation sequencing targeting approximately 110 thyroid cancer-related genes, including detection of mutations and copy number alterations, along with clinically actionable reports and malignancy risk assessments. Turnaround time for each test must not exceed two weeks from sample receipt, and the contractor must supply all necessary specimen collection and storage materials at no additional cost to the government. The evaluation process follows a Lowest Price Technically Acceptable (LPTA) methodology, where proposals are first screened for technical acceptability based on full compliance with the Statement of Work, and among those deemed acceptable, the award will go to the lowest-priced offeror. No trade-offs are permitted, and technical acceptability serves as a binary threshold with no numerical weighting applied. The solicitation applies standard FAR commercial items clauses under FAC 2026-01, including provisions for offeror representations, contract terms, and statutory compliance, all in unmodified form, and requires all offerors to be registered in SAM.gov with a valid UEI. The acquisition is capped at $350,000 and is not set aside for small businesses. Proposals must be submitted electronically to James.Law@nih.gov by July 27, 2026, at 9:00 AM, and while no specific file formats or page limits are mandated, submissions must demonstrate capability, include unit and total pricing, and meet all regulatory and compliance obligations outlined in FAR 52.212-1 through -5. No packaging, labeling, or security clearance requirements are specified, and the government retains final inspection and acceptance authority at the place of performance.